JP2018123138A - 半フッ化アルカンを基礎にした局所薬学的組成物 - Google Patents
半フッ化アルカンを基礎にした局所薬学的組成物 Download PDFInfo
- Publication number
- JP2018123138A JP2018123138A JP2018040265A JP2018040265A JP2018123138A JP 2018123138 A JP2018123138 A JP 2018123138A JP 2018040265 A JP2018040265 A JP 2018040265A JP 2018040265 A JP2018040265 A JP 2018040265A JP 2018123138 A JP2018123138 A JP 2018123138A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- composition according
- composition
- active ingredient
- sfa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
【解決手段】種々の活性成分、例えば免疫抑制薬、抗感染薬、抗真菌薬、抗炎症薬およびレチノイド等と下式で表される半フッ化アルカンを含む組成物。RFRH(式中、RFは、4〜12個の炭素原子を有する線状過フッ化炭化水素セグメントであり、そしてRHは、4〜8個の炭素原子を有する線状アルキル基である)
【選択図】なし
Description
− 10μm厚の1枚の薄片(角質層に対応する)
− 各々20μmの4枚の薄片(生きている表皮に対応する)
− 各々40μmの5×5枚の薄片(真皮の5つの層に対応する)。
Claims (15)
- 皮膚または皮膚付属器に影響を及ぼす疾患または症状の防止または処置に用いるための局所薬学的組成物であり、有効量の活性成分、および次式:
RFRH
(式中、RFは、4〜12個の炭素原子を有する線状過フッ化炭化水素セグメントであり、そしてRHは、4〜8個の炭素原子を有する線状アルキル基である)
で表わされる半フッ化アルカンを含む組成物であって、皮膚または皮膚付属器に投与される組成物。 - 前記半フッ化アルカンが、F4H5、F4H6、F4H8、F6H6およびF6H8(ここで、Fは過フッ化炭化水素セグメントを意味し、Hは非フッ化セグメントを意味し、そして数字はそれぞれのセグメントの炭素原子の数である)から選択される請求項1に記載の組成物。
- 液体、半固体溶液、乳濁液またはマイクロエマルションの形態である請求項1または2のいずれかに記載の組成物。
- 好ましくは、エタノール、アセトン、酢酸エチル、イソプロピルアルコール、グリセロール、プロピレングリコール、ペンチレングリコール、ポリエチレングリコール、液体パラフィン、トリグリセリド油、ヒドロフルオロカーボン:例えばHFA134aおよび/またはHFA227、および液体モノまたはジグリセリドから選択される生理学的に許容可能な共溶媒を含む請求項1〜3のいずれか一項に記載の組成物。
- 前記皮膚または皮膚付属器が、乾癬、皮膚炎、紅斑、湿疹、アレルギー、座瘡、光線性角化症、真菌感染症、細菌感染症、ウイルス感染症、疣または酒さから選択される疾患または症状により影響を及ぼされる、請求項1〜4のいずれか一項に記載の組成物。
- 前記疾患または症状が、皮膚の生きている表皮、真皮および/または皮下組織に影響を及ぼす、請求項1〜5のいずれか一項に記載の組成物。
- 前記皮膚が乾癬により影響を及ぼされ、前記活性成分が免疫抑制剤またはレチノイドから選択される請求項1〜6のいずれか一項に記載の組成物。
- 前記免疫抑制剤が、タクロリムス、シロリムス、エベロリムス、タクロリムス、ピメクロリムス、リダフォロリムス、テムシロリムス、ゾタロリムスおよびシクロスポリンAから選択される請求項7に記載の組成物。
- 前記レチノイドが、レチノール、レチナール、トレチノイン、イソトレチノイン、アリトレチノイン、エトレチネート、アシトレチン、タザロテン、ベキサロテンおよびアダパレンから選択される請求項7に記載の組成物。
- 前記皮膚が座瘡により影響を及ぼされ、前記活性成分がレチノイドまたは抗感染薬から選択される請求項1〜6のいずれか一項に記載の組成物。
- 前記レチノイドが、レチノール、レチナール、トレチノイン、イソトレチノイン、アリトレチノイン、エトレチネート、アシトレチン、タザロテン、ベキサロテンおよびアダパレンから選択される請求項10に記載の組成物。
- 前記抗感染薬が、アジスロマイシン、エリスロマイシン、クリンダマイシンまたはミノサイクリンから選択される請求項10に記載の組成物。
- 前記皮膚が光線性角化症により影響を及ぼされ、そして前記活性成分が、好ましくはジクロフェナク、5−フルオロウラシルおよびイミキモドから選択される請求項1〜6のいずれか一項に記載の組成物。
- 前記皮膚または皮膚付属器の疾患または症状により影響を及ぼされた患者を処置するための方法であって、請求項1〜13のいずれか一項に記載の薬学的組成物を前記皮膚または皮膚付属器に局所投与することを包含する方法。
- 皮膚の生きている表皮、真皮および/または皮下組織に活性成分を送達するための請求項1〜13のいずれか一項に記載の組成物の使用。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11167552 | 2011-05-25 | ||
EP11167552.6 | 2011-05-25 | ||
EP11167732.4 | 2011-05-26 | ||
EP11167732 | 2011-05-26 | ||
JP2016215748A JP6306126B2 (ja) | 2011-05-25 | 2016-11-03 | 半フッ化アルカンを基礎にした局所薬学的組成物 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016215748A Division JP6306126B2 (ja) | 2011-05-25 | 2016-11-03 | 半フッ化アルカンを基礎にした局所薬学的組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018123138A true JP2018123138A (ja) | 2018-08-09 |
JP6901421B2 JP6901421B2 (ja) | 2021-07-14 |
Family
ID=46168482
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014511893A Active JP6039145B2 (ja) | 2011-05-25 | 2012-05-24 | 半フッ化アルカンを基礎にした局所薬学的組成物 |
JP2016215748A Active JP6306126B2 (ja) | 2011-05-25 | 2016-11-03 | 半フッ化アルカンを基礎にした局所薬学的組成物 |
JP2018040265A Active JP6901421B2 (ja) | 2011-05-25 | 2018-03-07 | 半フッ化アルカンを基礎にした局所薬学的組成物 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014511893A Active JP6039145B2 (ja) | 2011-05-25 | 2012-05-24 | 半フッ化アルカンを基礎にした局所薬学的組成物 |
JP2016215748A Active JP6306126B2 (ja) | 2011-05-25 | 2016-11-03 | 半フッ化アルカンを基礎にした局所薬学的組成物 |
Country Status (13)
Country | Link |
---|---|
US (4) | US10130707B2 (ja) |
EP (3) | EP3311802B1 (ja) |
JP (3) | JP6039145B2 (ja) |
KR (2) | KR20170122282A (ja) |
CN (4) | CN103596554A (ja) |
AU (3) | AU2012260787B2 (ja) |
CA (1) | CA2834855C (ja) |
DK (2) | DK2714010T3 (ja) |
ES (3) | ES2962524T3 (ja) |
HK (1) | HK1247116A1 (ja) |
PL (2) | PL2714010T3 (ja) |
PT (2) | PT2714010T (ja) |
WO (1) | WO2012160179A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7360452B2 (ja) | 2018-09-27 | 2023-10-12 | ダーマリック セラピューティクス, インコーポレーテッド | 脂質バリアの修復 |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8545553B2 (en) | 2009-05-04 | 2013-10-01 | Valtech Cardio, Ltd. | Over-wire rotation tool |
EP2506777B1 (en) | 2009-12-02 | 2020-11-25 | Valtech Cardio, Ltd. | Combination of spool assembly coupled to a helical anchor and delivery tool for implantation thereof |
KR101656121B1 (ko) | 2010-03-17 | 2016-09-08 | 노바리크 게엠베하 | 안압 증가를 치료하기 위한 약학 조성물 |
EP2575685B1 (en) | 2010-06-07 | 2019-02-13 | Valtech Cardio, Ltd. | Apparatus for guide-wire based advancement of a rotation assembly |
EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
CN103596554A (zh) | 2011-05-25 | 2014-02-19 | 诺瓦利克有限责任公司 | 基于半氟化烷烃类的外用药物组合物 |
KR101773648B1 (ko) | 2011-05-25 | 2017-08-31 | 노바리크 게엠베하 | 조갑에 투여를 위한 제약학적 조성물 |
GB201120593D0 (en) * | 2011-11-29 | 2012-01-11 | Gsi Group Ltd | Gas bearing spindles and gas bearing assemblies for gas bearing spindles |
PL2806886T3 (pl) | 2012-01-23 | 2017-08-31 | Novaliq Gmbh | Stabilizowane kompozycje białkowe oparte na semifluorowanych alkanach |
CN106511322B (zh) | 2012-09-12 | 2021-09-17 | 诺瓦利克有限责任公司 | 包含半氟化烷烃的混合物的组合物 |
EP3488847B1 (en) | 2012-09-12 | 2023-11-08 | Novaliq GmbH | Semifluorinated alkane compositions |
AU2014209141B2 (en) | 2013-01-24 | 2018-05-10 | Palvella Therapeutics, Inc. | Compositions for transdermal delivery of mTOR inhibitors |
MX370207B (es) | 2013-07-23 | 2019-12-05 | Novaliq Gmbh | Composiciones estabilizadas de anticuerpos. |
US9522189B2 (en) * | 2013-12-20 | 2016-12-20 | Johnson & Johnson Consumer Inc. | Topical gel compositions including poly(monostearoyl glycerol-co-succinate) polymer and methods for enhancing the topical application of a benefit agent |
EP2944324A1 (de) * | 2014-05-13 | 2015-11-18 | LTS LOHMANN Therapie-Systeme AG | Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen |
PL3355990T3 (pl) | 2015-09-30 | 2019-11-29 | Novaliq Gmbh | Semifluorowane związki oraz ich kompozycje |
JP6642935B2 (ja) | 2015-09-30 | 2020-02-12 | ノバリック ゲーエムベーハー | 眼投与用の半フッ素化化合物 |
CN105663027B (zh) * | 2016-04-01 | 2018-12-18 | 中国人民解放军广州军区武汉总医院 | 西罗莫司外用制剂、其制备方法及用途 |
JP2019520357A (ja) | 2016-06-23 | 2019-07-18 | ノバリック ゲーエムベーハー | 局所投与方法 |
AU2017329772B2 (en) | 2016-09-22 | 2023-02-02 | Novaliq Gmbh | Pharmaceutical compositions for use in the therapy of blepharitis |
ES2965677T3 (es) | 2016-09-23 | 2024-04-16 | Novaliq Gmbh | Composiciones oftálmicas que comprenden ciclosporina |
US10751295B2 (en) * | 2016-11-09 | 2020-08-25 | Specialty Drug and Device, LLC | Compositions and methods for the removal of ear wax |
US20190328717A1 (en) | 2016-12-22 | 2019-10-31 | Novaliq Gmbh | Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases |
AU2018205253B2 (en) | 2017-01-06 | 2022-01-13 | Palvella Therapeutics, Inc. | Anhydrous compositions of mTOR inhibitors and methods of use |
WO2018193093A1 (en) * | 2017-04-21 | 2018-10-25 | Novaliq Gmbh | Iodine compositions |
WO2018206656A1 (en) | 2017-05-12 | 2018-11-15 | Novaliq Gmbh | Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions |
WO2018215638A1 (en) | 2017-05-26 | 2018-11-29 | Novaliq Gmbh | Pharmaceutical compositions comprising azithromycin |
KR20200059272A (ko) | 2017-09-27 | 2020-05-28 | 노바리크 게엠베하 | 안구 질환의 치료에서의 사용을 위한 라타노프로스트를 포함하는 안과적 조성물 |
WO2019068763A1 (en) | 2017-10-04 | 2019-04-11 | Novaliq Gmbh | OPHTHALMIC COMPOSITIONS COMPRISING F6H8 |
CA3091308A1 (en) | 2018-03-02 | 2019-09-06 | Novaliq Gmbh | Pharmaceutical compositions comprising nebivolol |
US11000513B2 (en) | 2018-07-02 | 2021-05-11 | Palvella Therapeutics, Inc. | Anhydrous compositions of mTOR inhibitors and methods of use |
PL3856128T3 (pl) * | 2018-09-27 | 2023-10-16 | Dermaliq Therapeutics, Inc. | Formulacja filtra przeciwsłonecznego do stosowania miejscowego |
CA3112031A1 (en) | 2018-10-12 | 2020-04-16 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
EP3861857A1 (en) * | 2020-02-07 | 2021-08-11 | Novaliq GmbH | Antiparasitic compositions |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0670159A1 (de) * | 1994-02-22 | 1995-09-06 | Hoechst Aktiengesellschaft | Fluorkohlenwasserstoffe enthaltende Ölemulsionen |
JP2000511157A (ja) * | 1995-09-29 | 2000-08-29 | マイネルト,ハッソ | セミフルオロアルカン及びその使用 |
JP2007508261A (ja) * | 2003-10-10 | 2007-04-05 | アンタレス ファルマ イーペーエル アクチェンゲゼルシャフト | 皮膚残留物を最小化するための経皮的医薬製剤 |
JP2008518891A (ja) * | 2004-11-02 | 2008-06-05 | スイッチ バイオテック アーゲー | Tリンパ球の増殖および/またはケラチノサイトの過剰増殖を特徴とする疾患、特にアトピー性皮膚炎および乾癬を処置するための、ピルリンドールの使用 |
WO2011009436A2 (de) * | 2009-07-24 | 2011-01-27 | Mika Pharma Gesellschaft Für Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh | Verfahren zur entwicklung einer als schaum auf die haut zu applizierende flüssige zusammensetzung sowie eine topisch applizierbare zusammensetzung |
Family Cites Families (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10022A (en) | 1853-09-13 | Lard-lamp | ||
US2616927A (en) | 1950-05-12 | 1952-11-04 | Minnesota Mining & Mfg | Fluorocarbon tertiary amines |
JPS5721312A (en) | 1980-07-12 | 1982-02-04 | Green Cross Corp:The | Breathable ointment |
US4452818A (en) | 1982-03-19 | 1984-06-05 | Haidt Sterling J | Extraocular method of treating the eye with liquid perfluorocarbons |
US5077036A (en) | 1986-01-14 | 1991-12-31 | Alliance Pharmaceutical Corp. | Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid |
JPH0764702B2 (ja) | 1986-04-23 | 1995-07-12 | 鐘紡株式会社 | 多相乳化型化粧料 |
JPS6452722A (en) | 1987-05-01 | 1989-02-28 | Anjierini Pharmaceut Inc | Ophthalmic composition |
JP3046346B2 (ja) | 1990-03-12 | 2000-05-29 | 昭和電工株式会社 | 外用剤基剤又は補助剤とそれを含有する人又は動物の外用剤 |
US5518731A (en) | 1990-09-27 | 1996-05-21 | Allergan, Inc. | Nonaqueous fluorinated drug delivery vehicle suspensions |
US6458376B1 (en) | 1990-09-27 | 2002-10-01 | Allergan, Inc. | Nonaqueous fluorinated drug delivery suspensions |
US5152997A (en) | 1990-12-11 | 1992-10-06 | Theratech, Inc. | Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels |
US5326566A (en) | 1991-05-17 | 1994-07-05 | Bristol-Myers Squibb Company | Use of dibutyl adipate and isopropyl myristate in topical and transdermal products |
FR2679150A1 (fr) | 1991-07-17 | 1993-01-22 | Atta | Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations. |
US5336175A (en) | 1992-10-29 | 1994-08-09 | Mames Robert N | Method for the treatment of retinal detachments |
FR2720943B1 (fr) | 1994-06-09 | 1996-08-23 | Applic Transferts Technolo | Emulsions inverses stables à forte concentration en composé(s) fluoré(s) et leur utilisation pour l'administration pulmonaire de médicaments et pour la fabrication d'émulsions multiples. |
US6294563B1 (en) | 1994-10-27 | 2001-09-25 | Allergan Sales, Inc. | Combinations of prostaglandins and brimonidine or derivatives thereof |
US5696164A (en) | 1994-12-22 | 1997-12-09 | Johnson & Johnson Consumer Products, Inc. | Antifungal treatment of nails |
US5667809A (en) | 1995-06-07 | 1997-09-16 | Alliance Pharmaceutical Corp. | Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents |
US5874481A (en) | 1995-06-07 | 1999-02-23 | Alliance Pharmaceutical Corp. | Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents |
US5874469A (en) | 1996-01-05 | 1999-02-23 | Alcon Laboratories, Inc. | Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs |
RU2111738C1 (ru) | 1996-06-24 | 1998-05-27 | Акционерное общество "НИЗАР" | Средство для усиления солнцезащитной активности фотозащитных агентов |
FR2752161B1 (fr) | 1996-08-07 | 1998-09-25 | Atta | Emulsions multiples de type hydrocarbure-dans-eau-dans- fluorocarbone pour le transport de substances medicamenteuses hydrophiles et/ou lipophiles |
US5863560A (en) | 1996-09-11 | 1999-01-26 | Virotex Corporation | Compositions and methods for topical application of therapeutic agents |
IN184589B (ja) | 1996-10-16 | 2000-09-09 | Alza Corp | |
DE19709704C2 (de) | 1997-03-10 | 1999-11-04 | Michael Georgieff | Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie |
US5980936A (en) | 1997-08-07 | 1999-11-09 | Alliance Pharmaceutical Corp. | Multiple emulsions comprising a hydrophobic continuous phase |
US5851544A (en) | 1997-12-18 | 1998-12-22 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Cosmetic skin or hair care compositions containing fluorocarbons infused with carbon dioxide |
US5981607A (en) | 1998-01-20 | 1999-11-09 | Allergan | Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers |
EP0983037B1 (en) | 1998-02-09 | 2003-05-02 | MacroChem Corporation | Antifungal nail lacquer |
DE19861012A1 (de) | 1998-03-18 | 1999-09-30 | Pharm Pur Gmbh | Behandlungsmittel für die Ophthalmologie |
IL141095A0 (en) | 1998-08-19 | 2002-02-10 | Rtp Pharma Inc | Injectable aqueous dispersions of propofol |
US6140374A (en) | 1998-10-23 | 2000-10-31 | Abbott Laboratories | Propofol composition |
US6159977A (en) | 1998-11-16 | 2000-12-12 | Astan, Inc. | Therapeutic anti-fungal nail preparation |
US7258869B1 (en) | 1999-02-08 | 2007-08-21 | Alza Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle |
IL144755A0 (en) | 1999-02-08 | 2002-06-30 | Alza Corp | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
AU3898700A (en) | 1999-03-15 | 2000-10-04 | John Claude Krusz | Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages |
US6177477B1 (en) | 1999-03-24 | 2001-01-23 | American Home Products Corporation | Propofol formulation containing TRIS |
US6239113B1 (en) | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
DE19926890C1 (de) | 1999-06-12 | 2000-07-27 | Pharm Pur Gmbh | Verwendung eines hochfluorierten oligomeren Alkans in der Ophthalmologie |
DE19938668B4 (de) | 1999-08-14 | 2006-01-26 | Bausch & Lomb Inc. | Tränenersatzmittel |
US6528086B2 (en) * | 1999-09-28 | 2003-03-04 | Zars, Inc. | Methods and apparatus for drug delivery involving phase changing formulations |
JP2001158734A (ja) | 1999-12-02 | 2001-06-12 | Lion Corp | 眼科用組成物及びソフトコンタクトレンズに対する吸着抑制方法 |
US20030018044A1 (en) | 2000-02-18 | 2003-01-23 | Peyman Gholam A. | Treatment of ocular disease |
DE10024413A1 (de) | 2000-05-19 | 2001-12-06 | Mika Pharma Gmbh | Pharmazeutische und/oder kosmetische Zubereitung |
DE10042412B4 (de) | 2000-08-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System zur Abgabe von Venlafaxin, und seine Verwendung |
US6399087B1 (en) | 2000-12-20 | 2002-06-04 | Amphastar Pharmaceuticals, Inc. | Propofol formulation with enhanced microbial inhibition |
WO2002089849A1 (en) | 2001-05-07 | 2002-11-14 | Corium International | Compositions and delivery systems for administration of a local anesthetic agent |
ES2299630T3 (es) | 2001-09-04 | 2008-06-01 | TROMMSDORFF GMBH & CO.KG ARZNEIMITTEL | Emplastos para la profilaxis y/o el tratamiento de disfunciones o trastornos del crecimiento de las uñas. |
AU2003206183A1 (en) | 2002-01-26 | 2003-09-02 | Micro Science Tech Co., Ltd | Composition containing moutan root bark extract as active ingredient |
EP2422768B1 (en) | 2003-08-25 | 2015-04-15 | Foamix Pharmaceuticals Ltd. | Penetrating pharmaceutical foam |
US20050079210A1 (en) | 2003-10-09 | 2005-04-14 | Gupta Shyam K. | Liposomal delivery system for topical pharmaceutical, cosmeceutical, and cosmetic ingredients |
CA2540621A1 (en) | 2003-11-19 | 2005-06-09 | Barnes-Jewish Hospital | Enhanced drug delivery |
GB0408164D0 (en) | 2004-04-13 | 2004-05-19 | Immune Targeting Systems Ltd | Antigen delivery vectors and constructs |
EP1740189B1 (en) | 2004-04-19 | 2012-06-13 | Centre National De La Recherche Scientifique -Cnrs- | Lung surfactant supplements |
JP2008501806A (ja) | 2004-06-08 | 2008-01-24 | オキュラリス ファーマ, インコーポレイテッド | 疎水性眼用組成物および使用方法 |
RU2007103835A (ru) | 2004-07-01 | 2008-08-10 | Шепенс Ай Рисерч (Us) | Композиции и способы лечения заболеваний и нарушений состояния глаз |
US7740875B2 (en) | 2004-10-08 | 2010-06-22 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
US20060078580A1 (en) | 2004-10-08 | 2006-04-13 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
GB0511499D0 (en) * | 2005-06-06 | 2005-07-13 | Medpharm Ltd | Topical ungual formulations |
ATE420625T1 (de) | 2005-08-05 | 2009-01-15 | Bharat Serums & Vaccines Ltd | Intravenöse propofol-emulsionszusammensetzungen mit konservierendem effekt |
FR2892023B1 (fr) | 2005-10-14 | 2009-09-25 | Galderma Sa | Composition pharmaceutique a base d'amorolfine et d'agent filmogene hydrosoluble pour application ungueale et peri-ungueale |
DE102005050431A1 (de) | 2005-10-21 | 2007-04-26 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System zur Verabreicherung lipophiler und/oder wenig hautpermeabler Wirkstoffe |
DE102005055811A1 (de) * | 2005-11-23 | 2007-05-31 | Novaliq Gmbh | Verwendung einer Zusammensetzung zur Konservierung von Organen und Gliedmaßen |
TWI376239B (en) | 2006-02-01 | 2012-11-11 | Andrew Xian Chen | Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof |
BRPI0714587A2 (pt) | 2006-07-25 | 2013-05-07 | Osmotica Corp | suluÇço oftÁlmica aquosa e uso da nesna |
JP5694664B2 (ja) | 2006-09-29 | 2015-04-01 | サーモディクス,インコーポレイティド | 生分解性眼用インプラント及び眼の病気を治療する方法 |
DE102007055046A1 (de) | 2007-11-19 | 2009-05-28 | Fluoron Gmbh | Infusionslösung |
US20090136430A1 (en) * | 2007-11-27 | 2009-05-28 | Dugger Harry A | Antihistamine/Corticosteroid preparations for the treatment of atopic dermatitis |
PL2110126T3 (pl) | 2008-04-18 | 2012-04-30 | Novaliq Gmbh | Zastosowanie do inhalacji i zakraplania semifluorowanych alkanów jako nośników substancji aktywnych w strefie wewnątrzpłucnej |
JP2012509737A (ja) | 2008-11-26 | 2012-04-26 | サーモディクス,インコーポレイティド | 埋め込み式の眼薬送達器具および眼薬送達方法 |
JP4642905B2 (ja) | 2009-01-22 | 2011-03-02 | 株式会社資生堂 | 乳化化粧料 |
US8501800B2 (en) | 2009-03-05 | 2013-08-06 | Insite Vision Incorporated | Controlled-release ophthalmic vehicles |
IT1393419B1 (it) | 2009-03-19 | 2012-04-20 | Medivis S R L | Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6. |
WO2010146536A1 (en) | 2009-06-18 | 2010-12-23 | Koninklijke Philips Electronics N.V. | Suspension of particles with drug |
JP5549669B2 (ja) | 2009-06-25 | 2014-07-16 | ライオン株式会社 | 眼科用組成物、ドライアイ治療剤及びビタミンaの安定化方法 |
JP5736635B2 (ja) | 2009-06-25 | 2015-06-17 | ライオン株式会社 | ドライアイ治療剤 |
EP2332525A1 (en) | 2009-11-23 | 2011-06-15 | Novaliq GmbH | Pharmaceutical composition comprising propofol |
EP2335735A1 (en) | 2009-12-14 | 2011-06-22 | Novaliq GmbH | Pharmaceutical composition for treatment of dry eye syndrome |
US20110223208A1 (en) | 2010-03-09 | 2011-09-15 | Beth Hill | Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations |
KR101656121B1 (ko) | 2010-03-17 | 2016-09-08 | 노바리크 게엠베하 | 안압 증가를 치료하기 위한 약학 조성물 |
DE102010022567A1 (de) | 2010-06-02 | 2011-12-08 | Fluoron Gmbh | Zubereitung |
EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
DK2661280T3 (en) | 2011-01-04 | 2019-03-04 | Novaliq Gmbh | O / V EMULSIONS INCLUDING SEMIFLUORINATED ALKANES |
US20120219640A1 (en) | 2011-02-25 | 2012-08-30 | Wright Kenneth W | Anti-infective solution for athlete's foot |
KR101773648B1 (ko) | 2011-05-25 | 2017-08-31 | 노바리크 게엠베하 | 조갑에 투여를 위한 제약학적 조성물 |
CN103596554A (zh) | 2011-05-25 | 2014-02-19 | 诺瓦利克有限责任公司 | 基于半氟化烷烃类的外用药物组合物 |
US8758826B2 (en) | 2011-07-05 | 2014-06-24 | Wet Inc. | Cannabinoid receptor binding agents, compositions, and methods |
PL2806886T3 (pl) | 2012-01-23 | 2017-08-31 | Novaliq Gmbh | Stabilizowane kompozycje białkowe oparte na semifluorowanych alkanach |
EP3488847B1 (en) | 2012-09-12 | 2023-11-08 | Novaliq GmbH | Semifluorinated alkane compositions |
CN106511322B (zh) | 2012-09-12 | 2021-09-17 | 诺瓦利克有限责任公司 | 包含半氟化烷烃的混合物的组合物 |
EP2783703A1 (en) | 2013-03-25 | 2014-10-01 | B. Braun Melsungen AG | Semifluorocarbon compound containing contrast agent |
MX370207B (es) | 2013-07-23 | 2019-12-05 | Novaliq Gmbh | Composiciones estabilizadas de anticuerpos. |
EP2944324A1 (de) | 2014-05-13 | 2015-11-18 | LTS LOHMANN Therapie-Systeme AG | Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen |
JP6642935B2 (ja) | 2015-09-30 | 2020-02-12 | ノバリック ゲーエムベーハー | 眼投与用の半フッ素化化合物 |
PL3355990T3 (pl) | 2015-09-30 | 2019-11-29 | Novaliq Gmbh | Semifluorowane związki oraz ich kompozycje |
CN106176937A (zh) | 2016-08-24 | 2016-12-07 | 刘艺鹏 | 湿疹、痤疮软膏 |
WO2018193093A1 (en) | 2017-04-21 | 2018-10-25 | Novaliq Gmbh | Iodine compositions |
PL3856128T3 (pl) | 2018-09-27 | 2023-10-16 | Dermaliq Therapeutics, Inc. | Formulacja filtra przeciwsłonecznego do stosowania miejscowego |
JP7360452B2 (ja) | 2018-09-27 | 2023-10-12 | ダーマリック セラピューティクス, インコーポレーテッド | 脂質バリアの修復 |
CN114206344A (zh) | 2019-08-09 | 2022-03-18 | 诺瓦利克有限责任公司 | 包含前列腺素类似物的局部组合物 |
EP3861857A1 (en) | 2020-02-07 | 2021-08-11 | Novaliq GmbH | Antiparasitic compositions |
-
2012
- 2012-05-24 CN CN201280025366.3A patent/CN103596554A/zh active Pending
- 2012-05-24 ES ES17201124T patent/ES2962524T3/es active Active
- 2012-05-24 EP EP17201124.9A patent/EP3311802B1/en active Active
- 2012-05-24 EP EP12723683.4A patent/EP2714010B1/en active Active
- 2012-05-24 CN CN201710375364.1A patent/CN107397718A/zh active Pending
- 2012-05-24 JP JP2014511893A patent/JP6039145B2/ja active Active
- 2012-05-24 KR KR1020177030042A patent/KR20170122282A/ko not_active Application Discontinuation
- 2012-05-24 WO PCT/EP2012/059787 patent/WO2012160179A2/en active Application Filing
- 2012-05-24 DK DK12723683.4T patent/DK2714010T3/en active
- 2012-05-24 AU AU2012260787A patent/AU2012260787B2/en active Active
- 2012-05-24 KR KR1020137033325A patent/KR101790388B1/ko active IP Right Grant
- 2012-05-24 CN CN201810782938.1A patent/CN109260193A/zh active Pending
- 2012-05-24 DK DK17154837.3T patent/DK3192501T3/da active
- 2012-05-24 PL PL12723683T patent/PL2714010T3/pl unknown
- 2012-05-24 EP EP17154837.3A patent/EP3192501B1/en active Active
- 2012-05-24 PT PT127236834T patent/PT2714010T/pt unknown
- 2012-05-24 US US14/122,044 patent/US10130707B2/en active Active
- 2012-05-24 CN CN201810165933.4A patent/CN108283623A/zh active Pending
- 2012-05-24 ES ES17154837T patent/ES2808051T3/es active Active
- 2012-05-24 PT PT171548373T patent/PT3192501T/pt unknown
- 2012-05-24 PL PL17154837T patent/PL3192501T3/pl unknown
- 2012-05-24 ES ES12723683.4T patent/ES2623233T3/es active Active
- 2012-05-24 CA CA2834855A patent/CA2834855C/en active Active
-
2016
- 2016-11-03 JP JP2016215748A patent/JP6306126B2/ja active Active
-
2017
- 2017-01-31 AU AU2017200622A patent/AU2017200622B2/en active Active
- 2017-09-29 US US15/721,259 patent/US10813999B2/en active Active
-
2018
- 2018-03-07 JP JP2018040265A patent/JP6901421B2/ja active Active
- 2018-05-25 HK HK18106802.5A patent/HK1247116A1/zh unknown
- 2018-07-20 AU AU2018206812A patent/AU2018206812B2/en active Active
-
2020
- 2020-10-16 US US17/072,923 patent/US11844836B2/en active Active
-
2022
- 2022-04-04 US US17/713,082 patent/US20220218828A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0670159A1 (de) * | 1994-02-22 | 1995-09-06 | Hoechst Aktiengesellschaft | Fluorkohlenwasserstoffe enthaltende Ölemulsionen |
JP2000511157A (ja) * | 1995-09-29 | 2000-08-29 | マイネルト,ハッソ | セミフルオロアルカン及びその使用 |
JP2007508261A (ja) * | 2003-10-10 | 2007-04-05 | アンタレス ファルマ イーペーエル アクチェンゲゼルシャフト | 皮膚残留物を最小化するための経皮的医薬製剤 |
JP2008518891A (ja) * | 2004-11-02 | 2008-06-05 | スイッチ バイオテック アーゲー | Tリンパ球の増殖および/またはケラチノサイトの過剰増殖を特徴とする疾患、特にアトピー性皮膚炎および乾癬を処置するための、ピルリンドールの使用 |
WO2011009436A2 (de) * | 2009-07-24 | 2011-01-27 | Mika Pharma Gesellschaft Für Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh | Verfahren zur entwicklung einer als schaum auf die haut zu applizierende flüssige zusammensetzung sowie eine topisch applizierbare zusammensetzung |
Non-Patent Citations (1)
Title |
---|
HENDRIK HARDUNG: "SEMIFLUORIERTE UND PERFLUORIERTE VERBINDUNGEN ZUR TOPISCHEN UND PARENTERALEN ANWENDUNG", [ONLINE], JPN5014007221, 18 August 2008 (2008-08-18), ISSN: 0004210208 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7360452B2 (ja) | 2018-09-27 | 2023-10-12 | ダーマリック セラピューティクス, インコーポレーテッド | 脂質バリアの修復 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6306126B2 (ja) | 半フッ化アルカンを基礎にした局所薬学的組成物 | |
KR101773648B1 (ko) | 조갑에 투여를 위한 제약학적 조성물 | |
AU2012260787A1 (en) | Topical pharmaceutical composition based on semifluorinated alkanes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180403 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180403 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190104 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190401 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190828 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191223 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20191223 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20200107 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20200121 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20200207 |
|
C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20200218 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20200827 |
|
C13 | Notice of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: C13 Effective date: 20201214 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210312 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20210413 |
|
C23 | Notice of termination of proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C23 Effective date: 20210413 |
|
C03 | Trial/appeal decision taken |
Free format text: JAPANESE INTERMEDIATE CODE: C03 Effective date: 20210525 |
|
C30A | Notification sent |
Free format text: JAPANESE INTERMEDIATE CODE: C3012 Effective date: 20210525 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210617 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6901421 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |